NRXS Stock Catalyst: Neuraxis Receives FDA Clearance for PENFS Technology to Treat Functional Abdominal Pain and Nausea

Neuraxis, Inc. (NRXS) announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for its Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The clearance allows the use of PENFS to treat functional abdominal pain and nausea associated with functional dyspepsia in patients aged 8 and older.

This clearance marks an important milestone for Neuraxis, enabling the company to offer a new non-pharmacological treatment option for a condition that affects a significant number of patients. The PENFS technology is designed to provide relief through targeted nerve stimulation without the need for invasive procedures.

Neuraxis has a free float of 7,430,800 shares and 9,986,300 shares outstanding.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.